Table of Contents
ISRN Gastroenterology
Volume 2011, Article ID 405390, 6 pages
http://dx.doi.org/10.5402/2011/405390
Research Article

Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients

1Department of Medicine, Division of Infectious Diseases and Immunology, New York University School of Medicine at Bellevue Hospital Center, New York, NY 10016, USA
2Division of Infectious Diseases, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ 07112, USA

Received 20 April 2011; Accepted 18 May 2011

Academic Editors: A. Nakajima, J. M. Pajares, and P. C. Y. Woo

Copyright © 2011 Christian A. Engell et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Lavanchy, “Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention,” Journal of Clinical Virology, vol. 34, no. 1, pp. S1–S3, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. “The Global HIV/AIDS pandemic,” Morbidity and Mortality Weekly Report, vol. 55, no. 31, pp. 841–844, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. P. J. Gaglio, R. Sterling, E. Daniels, and E. Tedaldi, “Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy,” Clinical Infectious Diseases, vol. 45, no. 5, pp. 618–623, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. J. H. Kim, G. Psevdos, J. Suh, and V. L. Sharp, “Co-infection of hepatitis B and hepatitis C virus in human immunodeficiency virus-infected patients in New York City, United States,” World Journal of Gastroenterology, vol. 14, no. 43, pp. 6689–6693, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Konopnicki, A. Mocroft, S. De Wit et al., “Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort,” AIDS, vol. 19, no. 6, pp. 593–601, 2005. View at Google Scholar · View at Scopus
  6. A. Lukhwareni, R. J. Burnett, S. G. Selabe, M. O. Mzileni, and M. J. Mphahlele, “Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a tertiary hospital,” Journal of Medical Virology, vol. 81, no. 3, pp. 406–412, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. L. H. Omland, N. Weis, P. Skinhøj et al., “Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study,” HIV Medicine, vol. 9, no. 5, pp. 300–306, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. K. Osborn, J. L. Guest, and D. Rimland, “Hepatitis B virus and HIV coinfection: relationship of different serological patterns to survival and liver disease,” HIV Medicine, vol. 8, no. 5, pp. 271–279, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. W. H. Sheng, J. H. Kao, P. J. Chen et al., “Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy,” Clinical Infectious Diseases, vol. 45, no. 9, pp. 1221–1229, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. H. M. Chun, A. M. Fieberg, K. H. Hullsiek et al., “Epidemiology of hepatitis B virus infection in a US cohort of HIV-infected individuais during the past 20 years,” Clinical Infectious Diseases, vol. 50, no. 3, pp. 426–436, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Rouet, M. L. Chaix, A. Inwoley et al., “Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-Infected children,” Clinical Infectious Diseases, vol. 46, no. 3, pp. 361–366, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. A. L. French, S. H. Gawel, R. Hershow et al., “Trends in mortality and causes of death among women with HIV in the United States: A 10-year study,” Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 4, pp. 399–406, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Lewden, T. May, E. Rosenthal et al., “Changes in causes of death among adults infected by HIV between 2000 and 2005: The “mortalité 2000 and 2005” surveys (ANRS EN19 and mortavic),” Journal of Acquired Immune Deficiency Syndromes, vol. 48, no. 5, pp. 590–598, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. F. J. Palella Jr., R. K. Baker, A. C. Moorman et al., “Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study,” Journal of Acquired Immune Deficiency Syndromes, vol. 43, no. 1, pp. 27–34, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Weber, C. A. Sabin, N. Friis-Moller et al., “Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study,” Archives of Internal Medicine, vol. 166, no. 15, pp. 1632–1641, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. G. K. Nikolopoulos, D. Paraskevis, E. Hatzitheodorou et al., “Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis,” Clinical Infectious Diseases, vol. 48, no. 12, pp. 1763–1771, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. A. De Luca, R. Bugarini, A. C. Lepri et al., “Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects,” Archives of Internal Medicine, vol. 162, no. 18, pp. 2125–2132, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. C. J. Hoffmann, S. Charalambous, D. J. Martin et al., “Hepatitis B virus infection and response to Antiretroviral Therapy (ART) in a South African ART Program,” Clinical Infectious Diseases, vol. 47, no. 11, pp. 1479–1485, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. J. J. Chang, S. Sirivichayakul, A. Avihingsanon et al., “Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection,” Journal of Virology, vol. 83, no. 15, pp. 7649–7658, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Puoti, C. Torti, R. Bruno, G. Filice, and G. Carosi, “Natural history of chronic hepatitis B in co-infected patients,” Journal of Hepatology, vol. 44, no. 1, supplement, pp. S65–S70, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. V. Soriano, M. Puoti, M. Peters et al., “Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel,” AIDS, vol. 22, no. 12, pp. 1399–1410, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Piroth, D. Sène, S. Pol et al., “Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY),” AIDS, vol. 21, no. 10, pp. 1323–1331, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. C. L. Thio, E. C. Seaberg, R. Skolasky et al., “HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS),” Lancet, vol. 360, no. 9349, pp. 1921–1926, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. C. L. Cooper, E. Mills, B. O. Wabwire et al., “Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa,” International Journal of Infectious Diseases, vol. 13, no. 3, pp. 302–306, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. F. Liaw, J. J. Y. Sung, W. C. Chow et al., “Lamivudine for patients with chronic hepatitis B and advanced liver disease,” New England Journal of Medicine, vol. 351, no. 15, pp. 1521–1587, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. M. K. Jain, “Mortality in patients coinfected with hepatitis B virus and HIV: could antiretroviral therapy make a difference?” Clinical Infectious Diseases, vol. 48, no. 12, pp. 1772–1774, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Martin-Carbonero and V. Soriano, “New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 3, pp. 379–382, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. DHHS, “Panel on antiretroviral guidelines for adults and adolescents, guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents,” in Services DoHaH, pp. 1–161, Department of Health and Human Services, USA, 2009. View at Google Scholar
  29. J. E. Kaplan, C. Benson, K. H. Holmes et al., “Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,” Morbidity and Mortality Weekly Report, vol. 58, no. 4, pp. 1–207, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. M. A. Thompson, J. A. Aberg, P. Cahn et al., “Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel,” Journal of the American Medical Association, vol. 304, no. 3, pp. 321–333, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. T. T. Chang, C. L. Lai, R. N. Chien et al., “Four years of lamivudine treatment in Chinese patients with chronic hepatitis B,” Journal of Gastroenterology and Hepatology, vol. 19, no. 11, pp. 1276–1282, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. A. S. Lok, C. L. Lai, N. Leung et al., “Long-term safety of lamivudine treatment in patients with chronic hepatitis B,” Gastroenterology, vol. 125, no. 6, pp. 1714–1722, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Benhamou, M. Bochet, V. Thibault et al., “Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients,” Hepatology, vol. 30, no. 5, pp. 1302–1306, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. G. V. Matthews, A. Bartholomeusz, S. Locarnini et al., “Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy,” AIDS, vol. 20, no. 6, pp. 863–870, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Wongprasit, W. Manosuthi, S. Kiertiburanakul, and S. Sungkanuparph, “Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy,” AIDS Patient Care and STDs, vol. 24, no. 4, pp. 205–209, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Iacomi, D. Vincenti, F. Vairo et al., “Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B,” Journal of Medical Virology, vol. 81, no. 7, pp. 1151–1156, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. A. S. Lok and B. J. McMahon, “Chronic hepatitis B: update 2009,” Hepatology, vol. 50, no. 3, pp. 661–662, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. C. L. Thio and S. Locarnini, “Treatment of HIV/HBV coinfection: clinical and virologic issues,” AIDS Reviews, vol. 9, no. 1, pp. 40–53, 2007. View at Google Scholar · View at Scopus
  39. G. V. Matthews, A. Avihingsanon, S. R. Lewin et al., “A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand,” Hepatology, vol. 48, no. 4, pp. 1062–1069, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. G. V. Matthews, E. Seaberg, G. J. Dore et al., “Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals,” AIDS, vol. 23, no. 13, pp. 1707–1715, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. M. K. Jain, L. Comanor, C. White et al., “Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response,” Journal of Viral Hepatitis, vol. 14, no. 3, pp. 176–182, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Schmutz, M. Nelson, T. Lutz et al., “Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection,” AIDS, vol. 20, no. 15, pp. 1951–1954, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Alvarez-Uria, L. Ratcliffe, and J. F. Vilar, “Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort,” HIV Medicine, vol. 10, no. 5, pp. 269–273, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Miailhes, P. Trabaud, P. Pradat et al., “Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion,” Clinical Infectious Diseases, vol. 45, no. 5, pp. 624–632, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Núñez, B. Ramos, B. Díaz-Pollán et al., “Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy,” AIDS Research and Human Retroviruses, vol. 22, no. 9, pp. 842–848, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Psevdos Jr., J. H. Kim, J. S. Suh, and V. L. Sharp, “Predictors of loss of hepatitis B surface antigen in HIV-infected patients,” World Journal of Gastroenterology, vol. 16, no. 9, pp. 1093–1096, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. J. J. Chang, F. Wightman, A. Bartholomeusz et al., “Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy,” Journal of Virology, vol. 79, no. 5, pp. 3038–3051, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Cooksley, S. Chokshi, Y. Maayan et al., “Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 1, pp. 312–320, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. J. You, H. Sriplung, A. Geater et al., “Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B,” World Journal of Gastroenterology, vol. 14, no. 7, pp. 1112–1119, 2008. View at Publisher · View at Google Scholar · View at Scopus